These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8948419)

  • 1. Serum prostate-specific antigen elevation in the post-radical prostatectomy patient.
    Malkowicz SB
    Urol Clin North Am; 1996 Nov; 23(4):665-75. PubMed ID: 8948419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Neulander EZ
    J Urol; 2004 Feb; 171(2 Pt 1):809; author reply 809-10. PubMed ID: 14713828
    [No Abstract]   [Full Text] [Related]  

  • 3. [Management of rising PSA after total prostatectomy].
    Zerbib M
    Ann Urol (Paris); 2007 Oct; 41 Suppl 3():S73-6. PubMed ID: 18297904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prostate cancer conundrum.
    Albertsen PC
    J Natl Cancer Inst; 2003 Jul; 95(13):930-1. PubMed ID: 12837821
    [No Abstract]   [Full Text] [Related]  

  • 5. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
    Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
    J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adjuvant medical treatment or radiotherapy following radical prostatectomy or curative radiotherapy].
    Guy L
    Bull Cancer; 2007 Jul; 94(7 Suppl):F15-20. PubMed ID: 17845989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.
    Choueiri TK; Chen MH; D'Amico AV; Sun L; Nguyen PL; Hayes JH; Robertson CN; Walther PJ; Polascik TJ; Albala DM; Moul JW
    Cancer; 2010 Apr; 116(8):1887-92. PubMed ID: 20162710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results].
    Hermans BP; Lorge F; Wese FX; Opsomer RJ; Van Cangh PJ
    Acta Urol Belg; 1996 Mar; 64(1):27-31. PubMed ID: 8659332
    [No Abstract]   [Full Text] [Related]  

  • 12. Despite PSA screening and the control by radical prostatectomy, patients treatment fails and have a PSA recurrence.
    Lotan Y
    Eur Urol; 2007 Aug; 52(2):453-4. PubMed ID: 17674436
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
    J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
    Yamamoto S; Kawakami S; Yonese J; Fujii Y; Urakami S; Masuda H; Numao N; Ishikawa Y; Kohno A; Fukui I
    Jpn J Clin Oncol; 2012 Jun; 42(6):541-7. PubMed ID: 22457326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
    Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
    Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy.
    Choo R; Hruby G; Hong J; Bahk E; Hong E; Danjoux C; Morton G; DeBoer G
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):269-76. PubMed ID: 12023129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant radiation, chemotherapy, and androgen deprivation therapy for pathologic stage D1 adenocarcinoma of the prostate.
    Freeman JA; Lieskovsky G; Grossfeld G; Esrig D; Stein JP; Cook DW; Petrovich Z; Chen SC; Groshen S; Skinner DG
    Urology; 1994 Nov; 44(5):719-25. PubMed ID: 7526528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.